Ketamine : friend or foe?
| dc.contributor.author | Steyn, Nicolene | |
| dc.date.accessioned | 2023-05-18T08:31:54Z | |
| dc.date.available | 2023-05-18T08:31:54Z | |
| dc.date.issued | 2023-09 | |
| dc.description.abstract | Ketamine, a dissociative anaesthetic drug, acts on the central nervous system (CNS) primarily through antagonism of the n-methyl-d-aspartate (NMDA) receptor. Methods of administration include intravenous, intramuscular, snorting and smoking. Intranasal use, which has a very rapid onset of action, is common among recreational users. | en_US |
| dc.description.department | Chemical Pathology | en_US |
| dc.description.librarian | hj2023 | en_US |
| dc.description.uri | http://jcp.bmj.com | en_US |
| dc.identifier.citation | Steyn, N. 2023, 'Ketamine: friend or foe?', Journal of Clinical Pathology, vol. 76, pp. 581, doi: 10.1136/jclinpath-2021-207586. | en_US |
| dc.identifier.issn | 0021-9746 (print) | |
| dc.identifier.issn | 1472-4146 (online) | |
| dc.identifier.other | 10.1136/jclinpath-2021-207586 | |
| dc.identifier.uri | http://hdl.handle.net/2263/90738 | |
| dc.language.iso | en | en_US |
| dc.publisher | BMJ Publishing Group | en_US |
| dc.rights | © Author(s) (or their employer(s)) 2023. No commercial re-use. | en_US |
| dc.subject | Ketamine | en_US |
| dc.subject | Dissociative anaesthetic drug | en_US |
| dc.subject | Central nervous system (CNS) | en_US |
| dc.subject | N-methyl-d-aspartate (NMDA) | en_US |
| dc.subject.other | Health sciences articles SDG-03 | |
| dc.subject.other | SDG-03: Good health and well-being | |
| dc.title | Ketamine : friend or foe? | en_US |
| dc.type | Postprint Article | en_US |